Pharmaceuticals 2012, 5(1), 79-93; doi:10.3390/ph5010079
Article

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors

Albert J. Chang 1 email, Ravindra DeSilva 2 email, Sandeep Jain 2 email, Kimberley Lears 1 email, Buck Rogers 1 email and Suzanne Lapi 2,* email
1 Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA 2 Department of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
* Author to whom correspondence should be addressed.
Received: 16 November 2011; in revised form: 14 December 2011 / Accepted: 22 December 2011 / Published: 5 January 2012
(This article belongs to the Special Issue Biologics)
PDF Full-text Download PDF Full-Text [699 KB, uploaded 5 January 2012 15:32 CET]
Abstract: The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20–30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases. Trastuzumab, an anti-HER2 monoclonal antibody, is used for the treatment of HER2 positive breast cancer and clinical efficacy of this agent is dependent on HER2 expression. Targeted PET imaging of HER2 with radiolabeled trastuzumab may be used to determine HER2 expression levels and guide therapy selection. The purpose of the current study was to evaluate a facile 89Zr-trastuzumab preparation method that can be efficiently applied for clinical grade production. Also, relative HER2 expression levels in orthotopic and metastatic breast cancer models were assessed by PET imaging using the 89Zr-trastuzumab produced by this simpler method.
Keywords: HER2; PET; 89Zr; immunoPET

Article Statistics

Click here to load and display the download statistics.

Cite This Article

MDPI and ACS Style

Chang, A.J.; DeSilva, R.; Jain, S.; Lears, K.; Rogers, B.; Lapi, S. 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals 2012, 5, 79-93.

AMA Style

Chang AJ, DeSilva R, Jain S, Lears K, Rogers B, Lapi S. 89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors. Pharmaceuticals. 2012; 5(1):79-93.

Chicago/Turabian Style

Chang, Albert J.; DeSilva, Ravindra; Jain, Sandeep; Lears, Kimberley; Rogers, Buck; Lapi, Suzanne. 2012. "89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors." Pharmaceuticals 5, no. 1: 79-93.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert